Results 91 to 100 of about 24,646 (191)

Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study

, 2011
Alyaa Ramadan1,4, Frederic Lagarce1,3, Anne Tessier-Marteau2, Olivier Thomas1, Pierre Legras5, Laurent Macchi2, Patrick Saulnier1, Jean Pierre Benoit1,31LUNAM Université, Ingénierie de la Vectorisation Particulaire, Inserm U-646 ...
Lagarce F, Tessier-Marteau A, Thomas O, Ramadan A, Benoit JP, Saulnier P, Legras P, Macchi L   +5 more
core  

Evaluation of bleeding risk in patients with renal impairment treated with Fondaparinux (Arixtra)

Journal of Applied Hematology, 2016
Background: Fondaparinux (Arixtra) a synthetic pentasaccharide that causes an antithrombin III-mediated selective inhibition of factor Xa. The clearance of fondaparinux reduces in patients with renal impairment, and there are no dosage adjustments ...
Hend H Metwali, Mohammed A Aseeri, Ahmed Mahmoud, Ahmad S Alsaeed, Mona E Albdelwahab, Abdul Salam, Rayf Abulezz   +6 more
doaj   +1 more source

Comparison of efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism in lower extremities after total hip arthroplasty and total knee arthroplasty: a retrospective study of 592 patients

BMC Surgery
Objectives To compare the efficacy of nadroparin and fondaparinux sodium for prevention of deep vein thromboembolism (DVT) in lower extremities after total hip arthroplasty (THA) and total knee arthroplasty (TKA).
Xiang Gao, Xiaowei Jin, Rui Huang, Zhenxing Li, Hanle Zhang, Pei Fan   +5 more
doaj   +1 more source

Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study

Journal of Blood Medicine, 2021
Giuseppe Cardillo,1 Giuseppe Vito Viggiano,2 Vincenzo Russo,3 Sara Mangiacapra,4 Antonella Cavalli,5 Giampiero Castaldo,2 Federica Agrusta,2 Annamaria Bellizzi Snr,5 Maria Amitrano Snr,4 Mariateresa Iannuzzo,6 Clara Sacco,7 Corrado Lodigiani,7 Andrea ...
Cardillo G, Viggiano GV, Russo V, Mangiacapra S, Cavalli A, Castaldo G, Agrusta F, Bellizzi Snr A, Amitrano Snr M, Iannuzzo M, Sacco C, Lodigiani C, Fontanella A, Di Micco P   +13 more
doaj  

Low Allergenic Potential With Fondaparinux: Results of a Prospective Investigation

, 2010
OBJECTIVE: To determine the incidence and causes of skin reactions to the synthetic pentasaccharide fondaparinux. PATIENTS AND METHODS: Patients who received prophylactic/therapeutic subcutaneous fondaparinux treatment for more than 7 days were ...
Marc Schindewolf, Hartmut Kroll, Schindewolf, Marc, Julia Scheuermann, Marzi, Ingo, Boehncke, Wolf-Henning, Hecking, Carola, Roland Kaufmann, Garbaraviciene, Jurate, Ludwig, Ralf J., Carola Hecking, Kroll, Hartmut, Wolf-Henning Boehncke, Manfred Wolter, Ingo Marzi, Scheuermann, Julia, Edelgard Lindhoff-Last, Jurate Garbaraviciene, Wolter, Manfred, Ralf J. Ludwig, Kaufmann, Roland, Lindhoff-Last, Edelgard   +21 more
core   +1 more source

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

, 2006
BACKGROUND The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes.
DCG Basart (14478804), T Hoskin (14478069), R Guerrero (7773575), A Rabelo (14478264), P Arasimowicz (14478870), W Zhu (7720097), A Janosi (14478624), HA Farras (14478114), JC Nicolau (14478252), GJ van Beek (14478840), M Galli (13553560), FWA Verheugt (14478858), H De Raedt (13445088), R Zadra (13588378), A Bin Othman (14478777), T Rebane (7628549), EC Schramm (14478210), GV Greque (14478288), N Grapsas (14478588), GJ de Weerd (14478813), S Thanikachalam (14478693), I Stoel (13569382), C Cuneo (13544959), E Ferrari (13326132), C Morillo (13445028), JP Bassand (14478009), J Johnson (5096225), B Meeks (13416948), C Convens (14478177), JAM Abrantes (14478246), MCG Daniels (14478810), LM Baracioli (14478249), JPR Herrman (14478822), O Happola (13553569), A Hrabar (13545013), A Maggioni (13539091), R Zaliunas (14478774), P Terrosu (14478759), L Piegas (13553521), JD Horowitz (13690300), P Cahill (13372977), BS Lewis (7759508), H Elliott (14478315), M Ramesh (9956330), KO Bischoff (14478516), S Yusuf (7635416), M Kenda (13554010), L Nagy (7656167), K Teo (13533226), D Hu (7807082), V Klauss (14478537), JP Albisu (14478096), M Montigny (14478357), IHGM Hendriks (14478819), PM van Kalmthout (14478852), J Ubaldini (14478153), S Yingxian (14478378), RB Panwar (14478681), J Roosen (14478195), CB Granger (14478012), R Sundararajan (13554100), A Martinoni (14478726), M Vrolix (14478204), P Bocek (14478399), I Macquin-Mavier (14478504), K Dominick (14478525), J Stumar (14478432), I Zakke (14478768), D Hunt (13394868), A Nambiar (14478678), J Rieber (14478558), Y Cottin (13553545), PG Steg (14478024), RD Mora (14478213), M Vacha (14478435), F Soeur (14478198), M Orlandi (14478741), C Constance (13566007), N Chidambaram (14478660), G New (13291383), E Gaxiola (13554040), M Richard (7713584), G Tulloch (14478168), A Czepiel (13553554), R Zanini (14478762), F Turazza (14478036), A Lichter (14478234), H Guelker (14478534), Z Davidovits (14478615), JP Coliet (14478477), B Petrauskiene (13554013), Y Ke (9865694), L Bolognese (14478705), JR Zhu (14478027), J Zaborski (13445145), M Mennuni (14478735), S Brons (14478297), I Fotiadis (14478582), K Thygesen (13539142), W Chen (774826), M Rokoss (14478087), JL Dubois-Rande (14478483), J Waites (13565953), P Ma (13469686), M Bakula (14478381), SK Li (14478603), T Davies (13363803), A Erglis (13416198), E Vigholt (14478438), G Amat (14478462), P Magloire (13569403), HR Michels (14478831), E Kristof (14478633), AJAM Withagen (14478864), A Lombardi (7776152), P Kalvach (13445118), S Connolly (13554607), J Renkin (13554094), A Lukin (14478384), R Nordaby (13415589), N Moschos (14478591), E Cohen (7937303), C Demers (14478084), JE Poulard (14478510), A Tyrologos (14478597), M Roy (7753250), T Lognone (14478501), A Avezum (7759511), MG Franzosi (7635368), PJ Devereaux (20436), T Baranowska (14478873), J vom Dahl (14478570), G Pacouret (14478507), A Parkhomenko (13317888), H Arabadzisz (14478606), D Severini (14478756), D Faxon (13554007), P Rossi (5821100), P Widimsky (10824582), Y Wu (808222), MWJ van Hessen (14478849), P Coussement (14478180), O Marcovitch (14478189), N Nguyen (11215299), J Narendra (13554073), S Radhakrishnan (13554091), EK Hayashi (14478231), M Branny (14478402), S Foussas (14478585), J Verboenko (14478765), J Amerena (13358346), EP Viergever (14478861), A Massaro (13340691), JD Amino (14478216), K Toth (13416267), R Yallup (14478081), L Janssens (13346031), M Flather (8412135), MA Hominal (14478120), K Peuhkurinen (13539082), B Schieffer (14478561), G Lupkovics (14478636), E Lonn (7800002), JA Marin-Neto (14478240), B Stockins (13554097), P Buszman (14478882), D Mitchell (9851267), PJS Gladstone (14478324), P Achremczyk (14478867), M Perez (5709848), D Chew (10737843), N Clappers (14478807), S Braekken (13554031), R Memoli (13415580), G Ramos-Lopez (14478798), D Alexopoulos (13554640), B Jedrzejowski (14478072), U Naslund (13554076), J Chen (80904), G Jingxuan (14478375), A Maresta (14478723), R Fouche (14478486), YK Chan (14478030), P Konecny (13458783), C Granger (13415919), O Jaboureck (14478492), N Blassopoulou (14478576), G Fodor (13445103), T Nitschke (14478552), AC Carvalho (8184378), A McCallum (14478354), G Aroney (14478156), M Bronisz (14478879), M Niemela (14478450), SR Mehta (7672538), S Ameriso (13340790), S Petronzelli (14478747), R Kuritzky (14478339), A Whelan (13565965), K Stangl (14478564), H White (7749056), V Jirka (14478417), AD Orlandini (14478135), RJG Peters (14478015), T Moccetti (13416492), M Pearce (11333421), M Heras (13554049), M Maly (13588393), J Csikazs (14478609), O Dutra (14478219), D Himbert (13553575), V Valentin (13553530), M Kaislerova (14478420), W Boden (13553998), RF Ramos (14478267), A Cassettari (14478111), G Piovaccari (14478750), M Oscipovsky (14478429), Y Lutay (13554070), T Huynh (10507223), E Papasteriadis (14478594), D Leys (7735199), U Buerke (14478522), LM Riera (14478129), L Ceremuzynski (13415217), HJ Rupprecht (14478021), G Gosselin (13588372), K Krasznai (14478828), A Weeks (13515118), K Al Shawafi (14478174), MERM van Daele (14478843), J Biegayto (14478876), T Moulin (13553176), AC Gutierrez (14478786), P Gregor (13554046), U Zeymer (14478573), N Karatzas (13553506), M Chenniappan (13554034), BJ van den Berg (14478846), O Koeth (14478543), PJ Commerford (14478018), R Kugiene (14478771), B Herczeg (13415427), S Varma (7797932), F Schiele (13416255), K Khalife (14478498), O Irkin (13554052), EM Marzetti (14478132), A Py (14478459), F Lanas (9967619), JM ten Berg (14478834), M LeMay (14478348), ERF Manenti (14478222), P Jansky (7800011), D Cross (9873755), P Leaes (14478207), P Costi (14478303), U Soopold (14478444), A Jain (7705433), J Van Lierde (14478201), SS Iyengar (14478033), VAWN Umans (14478837), M Schoeman (13727188), W Fan (9673223), WS Leung (14478600), G Reis (14478270), JP Esteves (14478261), J Kornder (14478336), P Jelinek (14478414), MCG Horrigan (14478165), P Laanmets (14478441), P Tuomainen (14478453), JFK Saraiva (14478228), D Fitzpatrick (9215723), G Bessede (14478465), A Lima (14478237), PRK Jain (14478669), T Dancs (14478612), A Ylitalo (14478456), E Swahn (13554025), C Gun (14478225), E Van Belle (14478039), M Senaratne (13588369), KJ Pistawka (14478360), J Healey (13553572), M Natarajan (6153719), T Budesinsky (14478405), L Mark (14478639), E Lundstrom (13444980), R Afzal (13445067), Z Rumboldt (13554019), G Meinhardt (14478546), RK Tongia (14478696), L Arnolda (13539238), LL Marquez (14478123), M Barbiero (14478699), J Pogue (13415178), J Weitz (12138732), O Salomone (14478147), S Janos (14478621), MC Guerrero (14478792), K Isaaz (13554055), MS Teixeira (14478276), D Bernardi (12140883), A Salvioni (14478753), Anna Peeters (13058832), S Vizel (13565986), J Huang (3663847), R Bhargava (14478294), C Melloni (14478729), J Sebo (14478651), M Lawrence (9883298), JL Anderson (7672556), LG Pancaldi (14478744), A de Meester (14478183), M Buerke (14478519), J Boschat (14478468), M Lamothe (14478345), R Dupuis (14478312), D El Allaf (14478186), F Grondin (14478327), L Moretti (14478738), FR dos Santos (14478273), H Vik-Mo (14478042), F Poor (14478645), B Witzenbichler (10824798), JJ Bluguermann (14478102), P Thompson (7635290), N Valettas (14478090), K Huber (9215618), J Voitk (13554622), F Leroy (12592756), OO Carlevaro (14478108), AC Diaz (14478789), CL Morales (14478795), A Christon (14478579), DA Fell (14478318), M Amuchastegui (13539160), F Holm (14478411), D Halon (13415262), GC MacCallum (14478351), C Horsman (14478066), K Chrysler (14478060), G Montalescot (13555993), BM Mayosi (9349844), P Petersen (13554085), G De Ferrari (14478711), VK Puri (14478687), D Carrie (14478471), A Nagy (14478642), H Ma (7778222), T Rajesh (14478690), DR Holmes (14478054), B Klosiewicz-Wasek (13554064), J Ge (7635275), FA Bello (14478099), G Grollier (14478489), I Lusic (13554067), JO Bono (14478105), P Dambrine (14478480), DS Silveira (14478279), AM Risolo (14478144), A Izzo (14478720), G Finet (13554037), ME Alcaino (14478372), L Capponi (14478708), M Penicka (13554079), J Varigos (13417008), J Sala (13712848), E Paolasso (13445037), E Kis (14478630), J Tomcsanyi (14478654), D deMets (14478051), G Milicevic (14478387), TM Jaison (14478672), J Stimac (14478363), KH Chee (14478780), B Yu (4702849), M Ruda (13416654), JL Chen (5160095), J Edington (13424538), LN Maia (14478255), P Boyd (14478159), B Cracknell (14478063), J Hirsh (14478048), R Ziffer (13415700), C Lauzon (13682350), SC Baldew (14478801), JA Piasentin (14478138), C Joyner (13444989), A Dacyk (14478306), PG Kerkar (14478675), M Aschermann (14478393), M Bergovec (13554616), A Pipilis (13553524), V Stangl (14478567), P Castro (7718291), HL Luciardi (14478126), H Drexler (14478528), L Csiba (13553548), P Pais (8718459), S Boccalon (14478057), R Fanelli (14478714), P Theroux (13554028), KK Haridas (14478663), HR Ramos (14478141), M Padovan (8546358), P van Rossum (14478855), S Kouz (13565995), J Velianou (14478093), J Morais (11347308), L Regos (14478648), PO Schygiel (14478150), CP Lau (14462736), HA Katus (10824810), G Marcinek (14478426), J Diodati (14478309), L Lisa (14478423), M Keltai (7759514), R Vaz (14478291), A Budaj (13415211), A Gorecki (13554043), I Janzen (14478330), L Groch (14478408), L Wallentin (7715258), M Smiley (14478078), JH Kim (7671248), E Cardona (13554001), N Jordanova (14478171), C Stevens (9360713), A Bharani (14478657), K Parikh (14478684), U Kalnins (13539097), G Haltern (13588462), M Kofflard (14478825), M Vico (13416045), J Puel (14478513), D Owensby (13415685), D Symeonidis (12139089), S Chrolavicius (13445064), E Sitkei (13553527), E Hasbani (13539181), MABT Lemos (14478282), B Charbonnier (14478474), D Xavier (7723550), CP Jaeger (14478258), B Singh (7755584), P Meneghetti (14478732), S Kotlan (14478075), J Col (13554004), P Sleight (13533178), A Timerman (14478285), R Ketelers (14478495), T Nielsen (13721665), S Naik (4656271), S Polic (13554088), S Labelle-Stimac (14478342), SK Hian (14478783), KAA Fox (7743407), I Edes (13555996), JT Counsell (14478162), L Muyldermans (14478192), J Smith (7785128), H Naveri (14478447), L Frediani (14478717), M Traboulsi (14478366), M Offterdinger (14478555), R Diaz (7759505), AY Fung (14478321), RH Zimmerman (14478369), A Feiler (14478531), J Fuselli (14478117), A Perakis (13554082), SPM Teixeira (14478243), G Bardelli (14478702), P Hicks (13653835), M Klutmann (14478540), E Gardinale (13553563), A Kadar (14478627), R McKelvie (9853781), M Laine (13445124), A Caccavo (13415946), M Colclough (14478300), M Raguz (14478390), FR den Hartog (14478816), J Belohlavek (14478396), A Garcia-Castillo (13565935), L Kevers (13554061), DE Johnstone (14478045), TM Muenzel (14478549), E Farkas (14478618), C Bonilla (13553539), D Robaayah (13554016), M Garrido (13544983), T Kalaparambath (14478333)   +494 more
core   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Development of an oral form of fondaparinux

, 2012
Le fondaparinux (Arixtra®), anticoagulant de la classe des pentasaccharides de synthèse, est le premier inhibiteur d'origine synthétique, spécifique et indirect du facteur Xa de la coagulation.
Ralay-Ranaivo, Bettina
core  

Safety of venous thromboembolism prophylaxis with fondaparinux in ischemic stroke

, 2015
IntroductionUnfractionated heparin (UFH), low molecular weight heparin or fondaparinux are recommended for venous thromboembolism (VTE) prophylaxis in acutely ill medical patients.
Hackett, C.T., Malhotra, K., Kelly, K.M., Wright, D.G., Ramanathan, R.S., Quigley, M.R., Tian, M., Protetch, J., Wong, C., Tayal, A.H.   +9 more
core   +1 more source

Überwachung der Antikoagulanzientherapie mit Fondaparinux

, 2005
ZusammenfassungIm Gegensatz zu niedermolekularem und unfraktioniertem Heparin besitzt Fondaparinux, ein synthetisch hergestelltes Pentasaccharid, einen selektiv hemmenden Effekt auf den Gerinnungsfaktor X.
E. Lindhoff-Last, G. Dämgen-von Brevern, C. Kläffling   +2 more
core   +1 more source